SCHEMBL4359755

SCHEMBL4359755

Oc1c(F)cccc1NCc1ccc(Br)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
EGFR P00533 1/20 0.35
THRB P10828 1/20 0.34
IDO1 P14902 1/20 0.34
L3MBTL1 Q9Y468 5/20 0.32
LMNA P02545 3/20 0.32
GAA P10253 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KMT2A Q03164 4/20 0.31
ALDH1A1 P00352 3/20 0.31
MAPT P10636 3/20 0.31
MEN1 O00255 3/20 0.31
TDP1 Q9NUW8 2/20 0.31
MITF O75030 1/20 0.31
USP2 O75604 1/20 0.31
ALOX12 P18054 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351154 0.82 MEN1 (0.32) EGFRTHRBKMT2AALDH1A1MAPT
SCHEMBL4352970 0.82 EGFR (0.38) KDM4EEGFRLMNASMN1; SMN2KMT2A
SCHEMBL4347704 0.76 EGFR (0.37) KDM4EEGFRL3MBTL1LMNAGAA
SCHEMBL16856424 0.71 HSD17B10 (0.50) KDM4ETHRBIDO1L3MBTL1NPC1
SCHEMBL4347156 0.71 EGFR (0.40) EGFRL3MBTL1LMNAKMT2AALDH1A1
SCHEMBL4354194 0.70 KMT2A (0.39) KDM4EEGFRTHRBLMNAGAA
SCHEMBL4346858 0.68 RXFP1 (0.49) KDM4EL3MBTL1GAASMN1; SMN2KMT2A
SCHEMBL18910578 0.67 NFKBIA (0.56) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL6566917 0.67 EGFR (0.33) EGFR
SCHEMBL4350086 0.67 L3MBTL1 (0.44) KDM4EL3MBTL1LMNAGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KDM4E 2662/4885EGFR 1661/4885THRB 367/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KDM4E 1689/4885EGFR 1635/4885THRB 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.